Baxdrostat lowers blood pressure and kidney damage markers in Phase 2 trial
Updated
Updated · SciTechDaily · May 9
Baxdrostat lowers blood pressure and kidney damage markers in Phase 2 trial
9 articles · Updated · SciTechDaily · May 9
In 192 chronic kidney disease patients with uncontrolled hypertension at 71 US sites, the pill beat placebo over 26 weeks and was published in the Journal of the American Society of Nephrology.
Participants started with average systolic pressure of 151 mm Hg and severe albuminuria; serious adverse events occurred in 9% on baxdrostat versus 3% on placebo, while high potassium was more frequent.
The AstraZeneca-funded drug is not FDA-approved, but Phase 3 studies are under way, including trials testing whether it can slow kidney disease progression and improve cardiovascular outcomes.
This new drug protects kidneys but raises potassium. With its FDA decision date past, how will doctors manage the risk?
A new pill helps failing kidneys, but so does Farxiga. Which drug will become the new standard of care?
Baxdrostat Lowers Systolic Blood Pressure by 9 mm Hg in Resistant Hypertension: Clinical Evidence, Mechanism, and Market Implications
Overview
Baxdrostat is a promising new treatment for resistant hypertension, currently under regulatory review with an FDA decision expected in 2026. Its New Drug Application is strongly supported by results from the BaxHTN Phase III trial, which showed significant reductions in systolic blood pressure for patients who did not respond to standard therapies. These findings were highlighted at a major cardiology conference and published in a leading medical journal, positioning baxdrostat for imminent approval. If approved, it could become the first therapy to specifically target excess aldosterone, offering new hope for patients with difficult-to-control blood pressure.